课题基金 / 基金详情

NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)

NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)
NABTC 中央运营补助金(加州大学旧金山分校项目负责人)
批准号:
6341965
负责人:
MICHAEL D PRADOS
金额:
$55.78万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-03-25 至 2002-12-31

项目摘要

项目成果

MICHAEL D PRADOS的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(申请人描述)
英文摘要
DESCRIPTION: (Applicant's Description) The Central Operations Office/Coordinating Center for this grant application is the administrative unit that will coordinate the activities of the North American Brain Tumor Consortium (NABTC) formed for the purpose of conducting laboratory and clinical Phase I and II research trials for adult patients with malignant brain tumors. The NABTC will be composed of seven treatment centers and 1 pharmacokinetics center, and will maintain a cooperative NABTC tissue bank. The NABTC will coordinate its efforts with the Cancer Therapy Evaluations Program (CTEP) and the Radiation Research Program (RRP) of the Division of Cancer Therapy to conduct novel therapies in this patient population. The Lead Institution of the NABTC is the University of California, San Francisco (UCSF), and the Project Leader is Michael Prados, MD. The Central Operations Office will provide coordination of protocol d e velopment and submissions, study conduct, quality control, protocol performance monitoring, statistical analysis, adherence to requirements regarding NCI drug accountability, FDA, OPRR and HHS regulations, and protocol and institutional performance reporting. Dr Prados will be the Principal Investigator of the Central Operations Office and thus will coordinate the clinical and administrative actives of the NABTC in order to achieve the NABTC goals with the assistance of CTEP. Part of these activities will be accomplished with a subcontract with the MD Anderson Cancer Center Data Management and Statistical Center, an operations center that has maintained a p e er-reviewed leadership role in its participation in consortium and intergroup studies. The end results of this NABTC Central Operations Office will be to assure quality, verifyable, coordinated research data that will allow ongoing rapid Phase II trials and laboratory investigations to be conducted in the most efficient manner possible in a patient population that thus far has little chance for survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE I STUDY OF OSI-774 AND TEMOZOLOMIDE FOR THE TREATMENT OF GLIOMAS
NABTC 01-08: PHASE II TRIAL OF STI571 (NSC 716051) IN RECURRENT MENINGIOMA
ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMA
A PHASE II TRIAL OF POLY ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA
海外基金